Susan Harden

3.7k total citations · 1 hit paper
72 papers, 2.0k citations indexed

About

Susan Harden is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiation. According to data from OpenAlex, Susan Harden has authored 72 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Pulmonary and Respiratory Medicine, 20 papers in Oncology and 17 papers in Radiation. Recurrent topics in Susan Harden's work include Lung Cancer Diagnosis and Treatment (39 papers), Lung Cancer Treatments and Mutations (29 papers) and Advanced Radiotherapy Techniques (17 papers). Susan Harden is often cited by papers focused on Lung Cancer Diagnosis and Treatment (39 papers), Lung Cancer Treatments and Mutations (29 papers) and Advanced Radiotherapy Techniques (17 papers). Susan Harden collaborates with scholars based in United Kingdom, Australia and United States. Susan Harden's co-authors include David Sidransky, Yutaka Tokumaru, Jonathan I. Epstein, Cármen Jerónimo, Stephen Yang, Henning Usadel, James Engles, Peter V. Danenberg, K. D. Danenberg and Jan Brabender and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

Susan Harden

67 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial

2017 354 citations Corinne Faivre‐Finn, M. Snee et al. profile →

Peers

Countries citing papers authored by Susan Harden

Since Specialization

Citations

This map shows the geographic impact of Susan Harden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan Harden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan Harden more than expected).

Fields of papers citing papers by Susan Harden

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan Harden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan Harden. The network helps show where Susan Harden may publish in the future.

Co-authorship network of co-authors of Susan Harden

This figure shows the co-authorship network connecting the top 25 collaborators of Susan Harden. A scholar is included among the top collaborators of Susan Harden based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan Harden. Susan Harden is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Disparities in Timeliness and Guideline‐Concordant Treatment is Associated With Excess Mortality in Public Versus Private Lung Cancer Patients 2025 ·Asia-Pacific Journal of Clinical Oncology ·Jonathan Pham, Tiffany Lin, Eldho Paul, (unknown), (unknown), Matthew Conron, Gavin Wright, (unknown), Gary Richardson, Phillip Antippa, (unknown), Susan Harden, John Zalcberg, Rob G. Stirling	0
2	Effect of arc length on the deep learning prediction of monitor units in lung stereotactic ablative radiation therapy treatment 2025 ·Physica Medica ·(unknown), Lachlan McIntosh, (unknown), Jason Li, Susan Harden, Sandro Porceddu, Vanessa Panettieri, Nicholas Hardcastle	1
3	Lung cancer (internet‐based) Delphi (LUCiD): A modified eDelphi consensus process to establish Australasian clinical quality indicators for thoracic cancer 2024 ·Respirology ·(unknown), Emily Stone, Shalini Vinod, Tracy L. Leong, Paul Dawkins, Rob G. Stirling, Susan Harden, (unknown), Annette McWilliams, Kenneth J. O’Byrne, Gavin Wright, (unknown), (unknown), Shoni Philpot, Neal Navani, Fraser Brims, (unknown)	1
4	Utility of 30-Day Mortality Following Systemic Anti-Cancer Treatment as a Quality Indicator in Advanced Lung Cancer 2024 ·Clinical Lung Cancer ·(unknown), Benjamin Solomon, Susan Harden, Senthil Lingaratnam, Marliese Alexander	1
5	The impact of pre-treatment smoking status on survival after chemoradiotherapy for locally advanced non-small-cell lung cancer 2024 ·Lung Cancer ·(unknown), Marliese Alexander, Jing Xie, David Ball, Fiona Hegi‐Johnson, Nikki Plumridge, Shankar Siva, Mark Shaw, Susan Harden, Thomas John, Benjamin Solomon, (unknown), Michael MacManus	1
6	Standards of care in mesothelioma treatment 2020 ·British Journal of Cancer ·Susan Harden, Liz Darlison, Paul Beckett, Anna Bibby	5
7	Isotoxic Intensity Modulated Radiation Therapy in Stage III Non-Small Cell Lung Cancer: A Feasibility Study 2020 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), N. Bayman, K. Franks, (unknown), Susan Harden, (unknown), Gerard G. Hanna, Stephen Harrow, M. Hatton, (unknown), Fiona McDonald, W. David J. Ryder, Corinne Faivre‐Finn	15
8	18F-Fludeoxyglucose PET/CT in SCLC: Analysis of the CONVERT Randomized Controlled Trial 2019 ·Journal of Thoracic Oncology ·Prakash Manoharan, Ahmed Salem, Hitesh Mistry, (unknown), Susan Harden, P. J. Julyan, Imogen Locke, J. McAleese, R. McMenemin, N. Mohammed, M. Snee, (unknown), (unknown), Corinne Faivre‐Finn	20
9	Impact of organisation and specialist service delivery on lung cancer outcomes 2019 ·Thorax ·(unknown), Aamir Khakwani, Paul Beckett, Richard Hubbard, Neal Navani, Susan Harden, Ian Woolhouse	8
10	Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer 2018 ·BMJ Open ·John Conibear, (unknown), Yenting Ngai, Andrew Bates, Nicholas Counsell, R. Patel, David Eaton, Corinne Faivre‐Finn, John D. Fenwick, Martin Förster, Gerard G. Hanna, Susan Harden, Philip Mayles, Syed Moinuddin, David Landau	50
11	P2.16-21 Post-Treatment Survival Difference Between Lobectomy and Stereotactic Ablative Radiotherapy in Stage 1 Non-Small Cell Lung Cancer in England 2018 ·Journal of Thoracic Oncology ·Aamir Khakwani, Susan Harden, Neal Navani, Paul Beckett, Richard C. Hubbard	0
12	OA13.01 The Impact of [18F]fludeoxyglucose PET/CT in Small-Cell Lung Cancer: Analysis of the Phase 3 CONVERT Trial 2018 ·Journal of Thoracic Oncology ·(unknown), Ahmed Salem, Hitesh Mistry, (unknown), Susan Harden, P. J. Julyan, Imogen Locke, J. McAleese, R. McMenemin, N. Mohammed, M. Snee, (unknown), Susan L. Woods, Corinne Faivre‐Finn	1
13	Apples and pears? A comparison of two sources of national lung cancer audit data in England 2017 ·ERJ Open Research ·Aamir Khakwani, Ruth H. Jack, Sally Vernon, (unknown), (unknown), Susan Harden, Paul Beckett, Ian Woolhouse, Richard Hubbard	7
14	Resectable Clinical N2 Non–Small Cell Lung Cancer; What Is the Optimal Treatment Strategy? An Update by the British Thoracic Society Lung Cancer Specialist Advisory Group 2017 ·Journal of Thoracic Oncology ·Matthew Evison, Amelia Clive, (unknown), Helen Powell, Rachel Thomas, Robert Buttery, Vidan Masani, Susan Harden, (unknown), Ian Woolhouse	26
15	Evaluating Competing and Emerging Technologies for Stereotactic Body Radiotherapy and Other Advanced Radiotherapy Techniques 2015 ·Clinical Oncology ·(unknown), S. Thomas, Susan Harden, N.G. Burnet	13
16	Accelerated hypo-fractionated radiotherapy for non small cell lung cancer: Results from 4 UK centres 2013 ·Radiotherapy and Oncology ·Omar Din, Susan Harden, Emma Hudson, N. Mohammed, L. Pemberton, J.F. Lester, (unknown), L. Magee, Adnan Tufail, Ross Carruthers, (unknown), David Gilligan, M. Hatton	57
17	Quantitative GSTP1 Methylation and the Detection of Prostate Adenocarcinoma in Sextant Biopsies 2003 ·JNCI Journal of the National Cancer Institute ·Susan Harden	96
18	A method for reducing ovarian doses in whole neuro-axis irradiation for medulloblastoma 2003 ·Radiotherapy and Oncology ·Susan Harden, N. Twyman, David J. Lomas, Denise Williams, N.G. Burnet, M.V. Williams	11
19	Treatment of Localized Carcinoma of the Penis: A Survey of Current Practice in the UK 2001 ·Clinical Oncology ·Susan Harden, Li Tee Tan	15
20	HIV-Testing Study of Immigrants with Pulmonary Tuberculosis 1997 ·Scandinavian Journal of Infectious Diseases ·Alec Bonington, Susan Harden, Sarah R. Anderson, R.A. Wall, Robert N. Davidson	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact